{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:12:27Z","timestamp":1791637947150,"version":"4.3.4"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Xinhua Hospital","award":["13YJ15"],"award-info":[{"award-number":["13YJ15"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims\/Introduction<\/jats:title><jats:p>We aimed to evaluate the potential benefits and adverse effects of adding a mineralocorticoid receptor antagonist (<jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>) to angiotensin\u2010converting enzyme inhibitors (<jats:styled-content style=\"fixed-case\">ACEI<\/jats:styled-content>) and\/or angiotensin receptor blockers (<jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content>), as standard treatment in patients with diabetic nephropathy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>We scanned the Embase, PubMed and Cochrane Central Register of Controlled Trials databases for human clinical trials published in English until June 2016, evaluating renal outcomes in patients with diabetic nephropathy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 18 randomized controlled trials involving 1,786 patients were included. Compared with <jats:styled-content style=\"fixed-case\">ACEI<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content> alone, co\u2010administration of <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">ACEI<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content> significantly reduced urinary albumin excretion and the urinary albumin\u2013creatinine ratio (mean difference \u221269.38, 95% confidence intervals \u2212103.53 to \u221235.22, <jats:italic>P<\/jats:italic> &lt; 0.0001; mean difference \u2212215.74, 95% confidence intervals \u2212409.22 to \u221222.26, <jats:italic>P<\/jats:italic> = 0.03, respectively). A decrease of blood pressure was also found in the co\u2010administration of <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">ACEI<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content> groups. However, we did not observe any improvement in the glomerular filtration rate. There was a significant increase in the risk of hyperkalemia on the addition of <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content> to <jats:styled-content style=\"fixed-case\">ACEI<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content> treatment (relative risk 3.74, 95% confidence intervals 2.30\u20136.09, <jats:italic>P<\/jats:italic> &lt; 0.00001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These findings suggest that co\u2010administration of <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">ACEI<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content> has beneficial effects on renal outcomes with increasing the incidence of hyperkalemia.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.12629","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T23:27:47Z","timestamp":1484954867000},"page":"609-618","source":"Crossref","is-referenced-by-count":52,"title":["Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy"],"prefix":"10.1111","volume":"8","author":[{"given":"Li\u2010Jing","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Nephrology Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan\u2010Ni","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Emergency Putuo Hospital Shanghai University of Traditional Chinese Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian\u2010Ping","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Nephrology Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng\u2010Ru","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Nephrology Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.03.003"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2010.10.003"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.11.007"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2012.36.2.128"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr495"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0944"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.10.021"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1059819"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03585.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.9.2106"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00756.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001580"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft281"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1470320313481485"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1470320312460290"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2006.04390.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0b013e31816d78e9"},{"key":"e_1_2_7_19_1","first-page":"648","article-title":"Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: a pilot randomized clinical trial","volume":"4","author":"Ziaee A","year":"2013","journal-title":"Caspian J Intern Med"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-015-1106-2"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009070737"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000249708.44016.5c"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12029"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07460713"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(02)02333-6"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00240106"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S11816"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04102.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.03.066"},{"key":"e_1_2_7_31_1","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"29","author":"Bolignano D","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.505"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04750908"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1718"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.5812\/numonthly.12148"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00805-3"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-10-199511150-00003"},{"key":"e_1_2_7_38_1","first-page":"507","article-title":"A prospective double\u2010blind randomized placebo\u2010controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis","volume":"23","author":"Taheri S","year":"2012","journal-title":"Saudi J Kidney Dis Transpl"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdi.12629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.12629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T03:45:41Z","timestamp":1696218341000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.12629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/jdi.12629"],"URL":"https:\/\/doi.org\/10.1111\/jdi.12629","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}